Company news
Kalvista Pharmaceuticals, Inc. (NASDAQ:KALV) news
Kalvista Pharmaceuticals, Inc. news releases on 6ix. Latest, Feb 21, 2025: KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy…
Press releases — page 2
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
February 20, 2025
KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting
February 9, 2025
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
January 20, 2025
KalVista Appoints Jeb Ledell as Chief Operating Officer
December 15, 2024
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
December 4, 2024
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
November 25, 2024
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
November 3, 2024
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
November 3, 2024
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
October 27, 2024
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
October 17, 2024
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
October 3, 2024
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
September 29, 2024
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
September 25, 2024
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
September 9, 2024
KalVista Appoints Brian Piekos as Chief Financial Officer
September 9, 2024
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
September 5, 2024
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
September 4, 2024
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
September 2, 2024
KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium
August 28, 2024
KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema
August 14, 2024
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
July 10, 2024
KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
June 26, 2024
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
June 17, 2024
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
June 5, 2024
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
June 2, 2024
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
May 30, 2024
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
May 23, 2024
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
April 30, 2024
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
April 21, 2024
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
April 2, 2024
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
March 17, 2024
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
March 11, 2024
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
March 7, 2024
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
March 6, 2024
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
March 5, 2024
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 26, 2024
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 25, 2024
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
February 19, 2024
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 15, 2024
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
February 14, 2024
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
February 13, 2024
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
February 12, 2024
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology
December 19, 2023
KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
November 13, 2023
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
November 12, 2023
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
November 1, 2023
KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference
October 23, 2023
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
September 18, 2023
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA
August 27, 2023
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer
July 24, 2023